Elicio Therapeutics KOL event
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, everyone, and welcome to the Elicio Therapeutics virtual KOL event. At this time, all attendees are in a listen-only mode, and a question-answer session will follow the formal presentations. As a reminder, this call is being recorded, and a replay will be made available on the Elicio website following the conclusion of the event. I'd now like to turn the call over to Dr. Chris Haqq, Chief Executive Officer and Head of Research and Development at Elicio Therapeutics. Please go ahead, Chris. Great.
Thank you very much. It's a pleasure today to welcome you to our discussion of neoadjuvant and metastatic applications of camupepimut, the clinical development in KRAS-mutated pancreatic ductal adenocarcinoma. I'll introduce here just that we will today be making forward-looking statements, and if you have any further questions about that, please refer to the Elicio website. Today in our agenda, we're very privileged to have two speakers that are immensely knowledgeable in the treatment of pancreatic cancer, with Dr. Kevin Soares, Assistant Attending Surgeon on the Hepatopancreaticobiliary Service at Memorial Sloan Kettering Cancer Center. Dr. Soares is the principal investigator of the neoadjuvant phase I study incorporating camupepimut, and he'll speak about that, as we've received so many questions about the recent startup of that study. In addition, it's a pleasure to be joined today with Dr. Eileen O'Reilly.
Eileen is the Winthrop Rockefeller Endowed Chair in Medical Oncology at Memorial Sloan Kettering. She's the section head for Hepatopancreaticobiliary and Neuroendocrine Cancers in the GI Oncology Service, and she co-directs the David M. Rubenstein Center for Pancreatic Cancer Research at MSK. Today, we'll begin with the discussion of the neoadjuvant study design, and after the presentations today, we'll have time for a discussion and question and answer session. With that, let me please invite Dr. Soares to speak about the neoadjuvant study that's begun.
Great. Thank you, Chris, and thank you everyone for the opportunity to be here and discuss our ongoing work. I'll be really focusing on our ongoing phase I trial looking at neoadjuvant FOLFIRINOX and camupepimut and tislelizumab in the resectable, borderline resectable pancreas cancer. Next slide. You can hit that slide ahead a little bit there, Chris, please. You'll see here the survival curves for pancreas cancer. This is a lot of what drives Dr. O'Reilly and I's work every day. What we see is a large number of patients with this disease, and Chris, you can hit the slide one more time.
And what we constantly are running into is the fact that in these survival curves, when you look at these, the higher this tail of the curve is, the more patients are living a long time, and this X-axis is the amount of time they are alive from diagnosis. What becomes clear is that over the years, and this study looked from 1997 up to 2016, we have seen very little improvement in pancreas cancer, most importantly, very little improvement in long-term survivors. We are clearly in need of novel therapies, which is what we are here to discuss and push forward through our research work. Next slide. When we look at classically how novel therapies have been introduced, not just pancreas cancer, but cancers in general, we typically are focused in the metastatic setting.
We are trying to assess safety and then efficacy, but the reality is, when you look at pancreas cancer especially, 50% of patients are metastatic at the time of diagnosis, and we cannot cure those patients. That leaves the other 50% of patients with potentially curable disease, 20% of which can be removed at diagnosis, the other 30% which is advanced but localized. This is really the patient population where we have a chance for cure, and this is really where over the years, as novel medications have come up, where we have seen improvements in overall survival over the years, and this is a patient population that is highly motivated to give themselves the best shot through undergoing combinatorial therapies like surgery, chemotherapy, and other novel and promising therapies. Next slide. Granted surgery is the approach combined with chemotherapy that offers us the chance at cure, but what is clear is that chance is not nearly as high as it needs to be for these patients, particularly when they are undergoing these major operations with significant risk associated with them.
What do we take away when we resect a pancreas cancer patient? Technically, when I am done with an operation, that patient has no more evidence of cancer, but the reality is, that is probably not realistic. This cancer tends to spread very early on in its course, and distant spread ends up being a very common occurrence with five-year survival, even after surgery, just 17% in some series.
Additionally, as we look to understand how to implement novel therapies in patients before surgery and even after, we are very limited with what we have been able to accomplish, particularly when we look at these tumors and they are removed, we are not seeing significant responses consistently that would implicate that these therapies have been very effective. It is hard to move the field forward because we are not seeing a lot of data or analyses that can really tell us, okay, well, why is it not working or why is it working, and who are the patients we should target and how should we move forward to the next step? This really is our interest in trying to move promising therapies, more specifically like immunotherapy, into a neoadjuvant setting where we can answer a lot of these questions. First of all, can we help patients live longer?
Can we make this surgery a curative event more often than not, which is currently not the case. In addition to that, can we understand what's happening at the tumor level with these novel therapies so that we can actually understand what are stronger preoperative and perioperative strategies to combine surgery with other promising therapies? In doing so, we need studies that really understand what's happening clinically, but also biologically. How are these medications working? Next slide. This just gives you a sense of what's been done thus far in this setting.
I look first at the regimen, and you can see the regimens that have been used most often in a neoadjuvant setting are basically the same chemotherapies we've been using for years now that have produced the numbers that I showed you in that first slide, and it's really reshuffling the different types of systemic chemotherapies. Not until recently are we seeing an interesting development of using targeted therapies and immunotherapies. If you go to the next red box, what you can see there in the CR is complete response or pathologic complete response. It's essentially, at best, 10%, but realistically 0%-3%. Even the median path response, where you get an overall higher response throughout the tumor, is still limited to about 20% of all the patients.
In doing so, what we're seeing at the end of the day is very minimal improvement in overall survival and disease-free survival, meaning we're still not curing a large percentage of patients. Next slide. This is really the thought process behind the current trial we have ongoing, where we have patients who have a high chance of being able to get to surgery, but they need neoadjuvant therapy first in order to control their disease and control for the potential for spread, even though the scans do not show it. This is a patient population we target with this study where we implement not only the standard of care chemotherapy, but add neoadjuvant immunotherapies, which could potentially shrink the tumor, facilitate surgery, but more importantly, potentially help activate the immune system and help it understand it needs to attack these cancer cells throughout the body.
That, by far, is our best defense against these microscopic cells that might be elsewhere that we can't address with surgery. By educating the immune system while the tumor's intact before surgery, we hope those T cells then go attack the tumor. We take the tumor out. We can understand if it's attacking the tumor once we analyze it. On top of that, then when the cancer's all gone and we realistically have microscopic disease left over, can address that with further immunotherapy and standard of care systemic therapies, all leading to what we hope is higher percentage of long-term cures, which come with a reduced chance of having the cancer come back, which ultimately can improve survival. Next slide. This approach is not something that's unique to pancreas cancer. We've actually seen the potential benefit of neoadjuvant immune approaches in other cancers.
This is a graph or a table demonstrating non-small cell lung cancer trials, triple-negative breast cancer trials, and even melanoma trials, all used in the neoadjuvant setting. The benefits here both being clinical, but understanding the biology where we can really understand how to implement these combinatorial therapies that we have at our disposal. Next slide. With that, I'll introduce the design that we have ongoing for our trial, which is a collaboration through Break Through Cancer and Lustgarten Foundation. It's a multi-institutional trial that's targeting patients, as I mentioned, with resectable or borderline resectable cancer. You can go onto the next slide. These patients, per standard of care, get full FOLFIRINOX, which is a standard of care chemotherapy. We typically do approximately four months of chemotherapy.
In this design, we are able to get their genetic testing done in the first two months while they get their standard of care chemotherapy, and then enroll them as their third month of treatment begins so that we can then give them chemotherapy combined with vaccine in one arm. In the second arm, it's chemotherapy combined with vaccine along with tislelizumab, which is an anti-PD-1 inhibitor. You can go to the next slide, Chris. That is completed all before surgery, and we have a window of opportunity between chemotherapy and surgery where we're able to give the immunotherapy on its own in those three weeks while the patients await surgery. Next slide. They then go on to potentially curative surgery, and then next slide, followed by adjuvant immunotherapy combined with chemotherapy, staying on the same paradigm that they were preoperatively.
Ultimately, once their chemotherapy is complete, next slide, we have the opportunity to do booster vaccinations. At the end, should their, when their cancer or if their cancer recurs, we have the opportunity to do biopsies. So we have a spectrum here of what's happening in these patients from beginning to end, meaning a biopsy prior to surgery and a biopsy at the time of surgery, which is a surgical resection, and then a recurrence, helping us understand resistance and response to the treatments we're implementing. Next slide. This is a two-arm study with 10 patients in each study, and the inclusion criteria, that's good, Chris, we can move to the next one, include patients with borderline resectable and resectable pancreas cancer containing these KRAS mutations with adequate performance status. Obviously, any patients with metastatic disease or unresectable disease are excluded. Next slide. This is really first evaluating the safety of combining chemotherapy with vaccine, with and without tislelizumab.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
9 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
